DSP2230 is primarily utilized in the field of oncology as a targeted therapy for specific types of cancers. It functions as a potent inhibitor of certain enzymes or proteins that are crucial for the survival and proliferation of cancer cells. By blocking these targets, DSP2230 effectively halts the growth of tumors and can induce apoptosis in malignant cells. This makes it a valuable component in the treatment regimen for patients with cancers that are resistant to conventional therapies. Additionally, DSP2230 is being investigated for its potential to enhance the efficacy of other cancer treatments when used in combination, offering a more comprehensive approach to combating the disease. Its targeted action also helps in minimizing damage to healthy cells, thereby reducing the side effects commonly associated with chemotherapy.